Corium
Corium is a commercial-stage biopharmaceutical company specializing in novel neuroscience therapies, focusing on ADHD and Alzheimer's Disease with products like AZSTARYS® and ADLARITY®.
Company Overview
Corium is a commercial-stage biopharmaceutical company that specializes in developing and commercializing novel neuroscience therapies. With a focus on Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's Disease, Corium has positioned itself as a leader in these therapeutic areas. The company's headquarters is located at 11 Farnsworth Street, 4th Floor, Boston, MA 02210.
Therapeutic Areas
Corium focuses on two main therapeutic areas: ADHD and Alzheimer's Disease. The company has developed products aimed at addressing the needs of patients with these conditions. Corium's efforts in these areas are underscored by their development of innovative drug delivery systems and once-daily or once-weekly formulations.
Products
Corium's product portfolio includes AZSTARYS® and ADLARITY®. AZSTARYS® (serdexmethylphenidate and dexmethylphenidate) is the first and only U.S. FDA-approved once-daily capsule for ADHD in patients aged 6 years and older. ADLARITY® (donepezil transdermal system) is the first and only U.S. FDA-approved once-weekly patch for patients with mild, moderate, and severe dementia of the Alzheimer's type. Both products offer unique delivery mechanisms and have demonstrated favorable outcomes in clinical trials.
FDA Approvals
AZSTARYS® received U.S. FDA approval in March 2021. This product has been shown to improve sleep habits in children with ADHD and has a low potential for abuse compared to dexmethylphenidate. ADLARITY® was approved by the U.S. FDA in March 2022 and is available for prescription in the U.S. for the treatment of Alzheimer's dementia. It provides drug exposure equivalent to oral donepezil and has a favorable gastrointestinal side effect profile.
Funding and Investments
Corium has secured significant financial backing to support its growth and development. The company received a $100 million equity investment from Webster Equity Partners to establish two independent growth companies. Additionally, Corium secured $235 million in debt financing from Hercules Capital, Inc. These investments underscore the confidence in Corium's strategic direction and product pipeline.